OGI vs. PAHC, STOK, NRIX, AUPH, TNGX, LBPH, GHRS, SAGE, LYEL, and ALXO
Should you be buying Organigram stock or one of its competitors? The main competitors of Organigram include Phibro Animal Health (PAHC), Stoke Therapeutics (STOK), Nurix Therapeutics (NRIX), Aurinia Pharmaceuticals (AUPH), Tango Therapeutics (TNGX), Longboard Pharmaceuticals (LBPH), GH Research (GHRS), Sage Therapeutics (SAGE), Lyell Immunopharma (LYEL), and ALX Oncology (ALXO). These companies are all part of the "pharmaceutical preparations" industry.
Phibro Animal Health (NASDAQ:PAHC) and Organigram (NASDAQ:OGI) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, community ranking, risk, media sentiment and valuation.
Phibro Animal Health has a net margin of 1.32% compared to Phibro Animal Health's net margin of -188.38%. Organigram's return on equity of 17.11% beat Phibro Animal Health's return on equity.
In the previous week, Phibro Animal Health and Phibro Animal Health both had 2 articles in the media. Phibro Animal Health's average media sentiment score of 0.93 beat Organigram's score of 0.81 indicating that Organigram is being referred to more favorably in the news media.
Phibro Animal Health has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500. Comparatively, Organigram has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500.
Phibro Animal Health has higher revenue and earnings than Organigram. Organigram is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.
Phibro Animal Health presently has a consensus price target of $14.75, indicating a potential downside of 16.34%. Given Organigram's higher probable upside, research analysts plainly believe Phibro Animal Health is more favorable than Organigram.
Phibro Animal Health received 108 more outperform votes than Organigram when rated by MarketBeat users. However, 70.61% of users gave Organigram an outperform vote while only 59.92% of users gave Phibro Animal Health an outperform vote.
99.3% of Phibro Animal Health shares are owned by institutional investors. Comparatively, 34.6% of Organigram shares are owned by institutional investors. 50.1% of Phibro Animal Health shares are owned by insiders. Comparatively, 0.1% of Organigram shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Phibro Animal Health beats Organigram on 11 of the 16 factors compared between the two stocks.
Get Organigram News Delivered to You Automatically
Sign up to receive the latest news and ratings for OGI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OGI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Organigram Competitors List
Related Companies and Tools
